All In Biotech

Drug Trial Radar · NCT06985706

Anti-vascular Endothelial Growth Factor (Anti-VEGF) Monotherapy vs Anti-VEGF Followed by Subthreshold Micropulse Laser for Treating Severe Diabetic Macular Oedema When the Central Retina Goes <400 Microns

Treatment of Severe Diabetic Macular Oedema With Anti-vascular Endothelial Growth Factor (Anti-VEGF) Monotherapy vs Anti-VEGF Followed by Subthreshold Micropulse Laser When the Thickness of the Central Retina Goes Below 400 Microns: Pragmatic Randomised Equivalence Trial

Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 264 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

264

Planned (sponsor's estimate)

Start

May 19, 2025

Primary completion

Nov 30, 2028

Study completion Nov 30, 2028

Sponsor

Lead sponsor
Belfast Health and Social Care TrustAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Queen's University, Belfast
First posted
May 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The macula is the centre of the retina; it gives central sight, colour and fine detail. People with diabetes may develop diabetic macular oedema (DMO). In DMO, fluid leaks from blood vessels and builds up at the macula, causing sight loss. DMO can be mild or severe; this is determined by measuring, in microns (µm), how thick the macula is. One µm is one-thousandth of a millimetre. People presenting with mild DMO (macula less than 400 µm thick; normally it is around 250 µm but varies with sex and ethnicity) are offered macular laser treatment. Laser works well for these patients. Subthreshold micropulse laser (SML), which does not damage the macula, works as well as standard laser, which produces a burn, and is cost-effective. However, many people present with severe DMO (macula 400 µm or thicker) where the laser does not work well. The standard treatment is eye injections of anti-VEGFs. VEGF stands for vascular endothelial growth factor. VEGF is high in eyes with DMO and causes blood vessel leakage. Anti-VEGFs block VEGF. They are given monthly to begin with, then every 2-3 months for months or years until DMO clears. In many patients DMO comes back after clearing and anti-VEGFs need to be re-started most often monthly initially again. To improve the care of people with severe DMO this study will compare the current standard care (anti-VEGFs alone) with a strategy in which patients begin with an anti-VEGF but switch to SML once the macula is less than 400 µm thick. Patients aged over 18 years with type 1 or type 2 diabetes and severe DMO can participate. They are randomly allocated either anti-VEGFs alone or anti-VEGFs then SML when the macula is less than 400 µm thick.

Conditions

  • Severe Diabetic Macular Oedema

Interventions

  • Subthreshold Micropulse Laser (SML)Procedure

    SML will be applied in line with the DAME Guideline and follow the DAME participant pathway.

  • Anti-VEGF Monotherapy (standard care)Drug

    Anti-VEGFs including ranibizumab and biosimilars, aflibercept, faricimab, and brolucizumab will be used, as per the standard of care at participating sites. The anti-VEGF should be administered in line with the summary of product characteristics (SmPC).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Best-Corrected Visual Acuity (BCVA)Time frame: 104 weeks after randomisation

Locations

22 sites in 1 country. Site status is shown where the registry gives one.

  • Bedford Hospital

    Bedford, United Kingdom · Recruiting

  • The Royal Hospitals Belfast

    Belfast, United Kingdom · Recruiting

  • Birmingham and Midland Eye Centre

    Birmingham, United Kingdom · Recruiting

  • Sussex Eye Hospital

    Brighton, United Kingdom · Recruiting

  • Bristol Eye Hospital

    Bristol, United Kingdom · Recruiting

  • Frimley Park Hospital

    Camberley, United Kingdom · Recruiting

  • University Hospital of Wales

    Cardiff, United Kingdom · Not yet recruiting

  • Gloucestershire Royal Hospital

    Gloucester, United Kingdom · Recruiting

  • Hull Royal Infirmary

    Hull, United Kingdom · Recruiting

  • Royal Liverpool University Hospital

    Liverpool, United Kingdom · Recruiting

  • Central Middlesex Hospital

    London, United Kingdom · Recruiting

  • Chelsea and Westminster Hospital

    London, United Kingdom · Recruiting

  • Kings College Hospital

    London, United Kingdom · Recruiting

  • Moorfields Eye Hospital

    London, United Kingdom · Recruiting

  • James Cook Hospital

    Middlesbrough, United Kingdom · Recruiting

  • Royal Gwent Hospital

    Newport, United Kingdom · Recruiting

  • Queen's Medical Centre

    Nottingham, United Kingdom · Not yet recruiting

  • University Hospital Southampton

    Southampton, United Kingdom · Recruiting

  • Sunderland Eye Hospital

    Sunderland, United Kingdom · Recruiting

  • Singleton Hospital

    Swansea, United Kingdom · Recruiting

  • Torbay Hospital

    Torquay, United Kingdom · Recruiting

  • Hillingdon Hospital

    Uxbridge, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.